{"ticker": {"uuid": "77a7233f-7b59-4d6d-8673-822af6693f1e", "symbol": "BIOA", "name": "BioAge Labs, Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Drug Manufacturers - Specialty & Generic"}, "articles": [{"title": "HitGen Partner BioAge Labs Doses First Participant In Phase 2 Trial Of BGE-102", "summary": "HitGen's partner, BioAge Labs, has dosed the first participant in its Phase 2 trial of BGE-102. This marks a significant step forward in the development of the therapeutic candidate.", "url": "https://www.tradingview.com/news/reuters.com,2026:newsml_TUA88ZXV4:0-hitgen-partner-bioage-labs-doses-first-participant-in-phase-2-trial-of-bge-102/", "source_name": "TradingView", "published_at": "2026-07-14T15:13:40", "published_display": "14 Jul 2026 15:13", "sentiment": "positive", "sentiment_pct": 69, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "HitGen partner BioAge begins phase 2 trial of BGE-102", "summary": "HitGen Inc. announced that its partner BioAge Labs has started a Phase 2 clinical trial for BGE-102, an oral small molecule NLRP3 inhibitor aimed at reducing cardiovascular risk. The trial, named QUELL-CV, will evaluate optimal dosing for future Phase 3 development and is expecte", "url": "https://www.investing.com/news/company-news/hitgen-partner-bioage-begins-phase-2-trial-of-bge102-93CH-4791083", "source_name": "Investing.com", "published_at": "2026-07-14T13:46:15", "published_display": "14 Jul 2026 13:46", "sentiment": "positive", "sentiment_pct": 91, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "HitGen Partner BioAge Labs Doses First Participant in Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor for Cardiovascular Risk Reduction", "summary": "HitGen's partner, BioAge Labs, has dosed the first participant in its Phase 2 QUELL-CV trial for BGE-102, a novel oral NLRP3 inhibitor developed using HitGen's DNA-Encoded Library (DEL) technology. This trial aims to determine optimal dosing for cardiovascular risk reduction, wit", "url": "https://www.prnewswire.com/news-releases/hitgen-partner-bioage-labs-doses-first-participant-in-phase-2-trial-of-bge-102-a-novel-oral-nlrp3-inhibitor-for-cardiovascular-risk-reduction-302824829.html", "source_name": "PR Newswire", "published_at": "2026-07-14T13:30:15", "published_display": "14 Jul 2026 13:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Broad Russell Growth Index Inclusion Could Shape BioAge Labs (BIOA) Investor Exposure", "summary": "BioAge Labs (BIOA) was recently added to several Russell Growth Benchmark Indexes, increasing its visibility among institutional investors but not fundamentally changing its core investment risks or near-term catalysts. The investment case hinges on the success of its lead asset ", "url": "https://www.sahmcapital.com/news/content/how-broad-russell-growth-index-inclusion-could-shape-bioage-labs-bioa-investor-exposure-2026-07-10", "source_name": "Sahm", "published_at": "2026-07-11T01:09:23", "published_display": "11 Jul 2026 01:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioAge advances inflammaging drug into Phase 2", "summary": "BioAge has initiated its Phase 2 QUELL-CV trial to evaluate its NLRP3 inflammasome inhibitor, BGE-102, for cardiovascular inflammatory burden. This drug was discovered through human longevity datasets, aiming to address chronic inflammation (inflammaging) which is a key hallmark ", "url": "https://longevity.technology/news/bioage-advances-inflammaging-drug-into-phase-2/", "source_name": "Longevity.Technology", "published_at": "2026-07-07T16:12:12", "published_display": "07 Jul 2026 16:12", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of BioAge Labs, Inc. \u2013 NASDAQ:BIOA", "summary": "This article provides the \"Price to sales forward\" metric for BioAge Labs, Inc. (NASDAQ:BIOA). The data is presented within the context of TradingView's financial overview for the company, accessible through its platform.", "url": "https://www.tradingview.com/symbols/NASDAQ-BIOA/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-07T03:41:07", "published_display": "07 Jul 2026 03:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of BioAge Labs, Inc. \u2013 DUS:Y7G", "summary": "This article displays information regarding the \"Price to earnings forward\" metric for BioAge Labs, Inc. (DUS:Y7G) on the Dusseldorf Stock Exchange. It indicates that no specific value, change, or percentage change for this financial metric was available at the time of publicatio", "url": "https://www.tradingview.com/symbols/DUS-Y7G/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-07T00:39:19", "published_display": "07 Jul 2026 00:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of BioAge Labs, Inc. \u2013 DUS:Y7G", "summary": "This page from TradingView provides financial information for BioAge Labs, Inc. (DUS:Y7G), specifically focusing on its Enterprise Value to EBITDA forward. The content indicates that market data is provided by ICE Data Services and FactSet, highlighting key financial metrics for ", "url": "https://www.tradingview.com/symbols/DUS-Y7G/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-06T21:40:01", "published_display": "06 Jul 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bioage Labs stock hits 52-week high at 25.8 USD", "summary": "Bioage Labs (BIOA) stock recently hit a 52-week high of $25.8, currently trading at $25.53 with a market capitalization of $1.12 billion, reflecting a 486% increase over the past year. This surge is supported by positive developments, including the dosing of the first participant", "url": "https://www.investing.com/news/company-news/bioage-labs-stock-hits-52week-high-at-258-usd-93CH-4776825", "source_name": "Investing.com", "published_at": "2026-07-06T14:41:07", "published_display": "06 Jul 2026 14:41", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why BioAge Labs (BIOA) Is Up 6.3% After Starting QUELL-CV Phase 2 Trial For BGE-102", "summary": "BioAge Labs (BIOA) has started its QUELL-CV Phase 2 trial for BGE-102, an oral NLRP3 inhibitor targeting cardiovascular risk reduction, leading to a 6.3% increase in its stock price. This move advances the company's pipeline and focuses investor attention on its inflammation-targ", "url": "https://www.sahmcapital.com/news/content/why-bioage-labs-bioa-is-up-63-after-starting-quell-cv-phase-2-trial-for-bge-102-2026-07-02", "source_name": "Sahm", "published_at": "2026-07-03T23:40:02", "published_display": "03 Jul 2026 23:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bioage Labs Insider Sold Shares Worth $1,576,752, According to a Recent SEC Filing", "summary": "An insider at Bioage Labs recently sold shares totaling $1,576,752, as detailed in a recent SEC filing. This transaction provides insights into insider activities at the company, which can often be a point of interest for investors.", "url": "https://www.moomoo.com/news/post/72352036/bioage-labs-insider-sold-shares-worth-1576752-according-to-a", "source_name": "Moomoo", "published_at": "2026-07-01T21:40:38", "published_display": "01 Jul 2026 21:40", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] BioAge Labs, Inc. Insider Trading Activity", "summary": "BioAge Labs, Inc.'s Principal Accounting Officer, Shane Barton, engaged in insider trading activity by exercising stock options and selling common stock shares in late June. These transactions, totaling 62,566 shares sold for approximately $1.58 million, were executed under a pre", "url": "https://www.stocktitan.net/sec-filings/BIOA/form-4-bio-age-labs-inc-insider-trading-activity-aab271d3fad7.html", "source_name": "Stock Titan", "published_at": "2026-07-01T20:53:58", "published_display": "01 Jul 2026 20:53", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioAge Labs principal accounting officer sells $1.57m in stock", "summary": "Shane Barton, Principal Accounting Officer at BioAge Labs, Inc. (NASDAQ:BIOA), sold 62,566 shares of the company's common stock for approximately $1.57 million between June 29 and June 30, 2026. These sales occurred after Barton acquired 59,934 shares through stock options and we", "url": "https://www.investing.com/news/insider-trading-news/bioage-labs-principal-accounting-officer-sells-157m-in-stock-93CH-4771539", "source_name": "Investing.com", "published_at": "2026-07-01T20:40:38", "published_display": "01 Jul 2026 20:40", "sentiment": "negative", "sentiment_pct": 35, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioAge Labs principal accounting officer sells $1.57m in stock By Investing.com", "summary": "BioAge Labs' principal accounting officer, Shane Barton, sold 62,566 shares of BioAge Labs (NASDAQ: BIOA) common stock for approximately $1.57 million across two trading days. These sales occurred after Barton exercised stock options to acquire 59,934 shares and were executed und", "url": "https://ca.investing.com/news/stock-market-news/bioage-labs-principal-accounting-officer-sells-157m-in-stock-93CH-4717028", "source_name": "Investing.com Canada", "published_at": "2026-07-01T20:39:59", "published_display": "01 Jul 2026 20:39", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Bioage Labs Inc For: 1 July By Investing.com", "summary": "This article reports on a Form 4 filing by Bioage Labs Inc. for July 1st, published by Investing.com. It also includes a stock market overview with various indices, commodity prices, and individual stock performances, alongside popular news headlines.", "url": "https://ca.investing.com/news/stock-market-news/form-4-bioage-labs-inc-for-1-july-93CH-4717041", "source_name": "Investing.com Canada", "published_at": "2026-07-01T20:39:58", "published_display": "01 Jul 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BIOA (NASDAQ: BIOA) Form 144 filed for 42,350-share proposed sale", "summary": "BioAge Labs, Inc. (NASDAQ: BIOA) has filed a Form 144 indicating a proposed sale of 42,350 shares tied to a stock option exercise, with a planned sale date of June 30, 2026. The filing also reports a recent sale of 42,350 shares on June 29, 2026, generating $1,067,577.87, with Fi", "url": "https://www.stocktitan.net/sec-filings/BIOA/144-bio-age-labs-inc-sec-filing-06639cfc10ad.html", "source_name": "Stock Titan", "published_at": "2026-06-30T20:22:32", "published_display": "30 Jun 2026 20:22", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is BioAge Labs, Inc. (BIOA) Stock Positioned for Growth With New Phase 2 Cardiovascular Study Initiation?", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxNbnE4RUI3YzhkV1RkSkprZ2hoR2lYWE9fUkhIQkxSNEk0b0FucjZ4bUtlSVJqOW0wT0ZBZmFHZDZQbUlGNjY0LW4xXzZJdGFXNDBManMyWjlTTUU4WTJNU0xGNEppa0pTWVpzd2pYY18yX1ZFQUVfSmlMY3YwVU1tMHY0SUl3RlZtUkZBNUZGVWc?oc=5", "source_name": "Market source", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 BioAge Labs For: 29 June By Investing.com", "summary": "This article from Investing.com announces the filing of Form 144 for BioAge Labs on June 29. It briefly mentions the stock symbol BIOA, which saw a 5.01% increase, and is published by \u00a9 Reuters. The content mainly consists of market data and unrelated trending news and stock perf", "url": "https://ca.investing.com/news/stock-market-news/form-144-bioage-labs-for-29-june-93CH-4712570", "source_name": "Investing.com Canada", "published_at": "2026-06-29T21:09:16", "published_display": "29 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BIOA (BIOA) Form 144 lists proposed sales of 2,632 and 39,718 shares", "summary": "BioAge Labs, Inc. (BIOA) has filed a Form 144 notice with the SEC, indicating proposed sales of Common stock. The filing details two transactions: 2,632 \"IPO Shares\" dated September 26, 2024, and 39,718 shares from a \"Stock Option Exercise\" dated June 29, 2026. Fidelity Brokerage", "url": "https://www.stocktitan.net/sec-filings/BIOA/144-bio-age-labs-inc-sec-filing-ae490a06ed9a.html", "source_name": "Stock Titan", "published_at": "2026-06-29T20:09:16", "published_display": "29 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioAge Labs, Inc.(NasdaqGS: BIOA) added to Russell Microcap Growth Benchmark Index", "summary": "BioAge Labs, Inc. (NasdaqGS: BIOA) has been added to multiple Russell benchmark indices, including the Russell Microcap Growth, Russell 2000 Growth, Russell 3000E Growth, and Russell Small Cap Comp Growth. This inclusion is a significant milestone for the clinical-stage biopharma", "url": "https://www.marketscreener.com/news/bioage-labs-inc-nasdaqgs-bioa-added-to-russell-microcap-growth-benchmark-index-ce7f5fded08df123", "source_name": "marketscreener.com", "published_at": "2026-06-29T13:09:16", "published_display": "29 Jun 2026 13:09", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioAge Labs, Inc.(NasdaqGS: BIOA) added to Russell 2000 Growth Benchmark", "summary": "BioAge Labs, Inc. (NasdaqGS:BIOA) has been added to the Russell 2000 Growth Benchmark, a significant development for the clinical-stage biopharmaceutical company. The company focuses on developing therapeutic product candidates for metabolic diseases, such as obesity, by targetin", "url": "https://www.marketscreener.com/news/bioage-labs-inc-nasdaqgs-bioa-added-to-russell-2000-growth-benchmark-ce7f5fded18df026", "source_name": "marketscreener.com", "published_at": "2026-06-29T11:41:03", "published_display": "29 Jun 2026 11:41", "sentiment": "positive", "sentiment_pct": 86, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioAge Labs (BIOA) Following QUELL CV Trial Start Is The Stock A Bargain", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of BioAge Labs, Inc. \u2013 NASDAQ:BIOA", "summary": "This article provides a financial metric\u2014enterprise value to EBIT forward\u2014for BioAge Labs, Inc. (NASDAQ: BIOA). It serves as a financial data point without further analysis or contextual information. The content primarily focuses on the stock's listing and basic financial overvie", "url": "https://www.tradingview.com/symbols/NASDAQ-BIOA/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T14:41:41", "published_display": "27 Jun 2026 14:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of BioAge Labs, Inc. \u2013 GETTEX:Y7G", "summary": "This article provides financial information for BioAge Labs, Inc. (GETTEX:Y7G) focusing on its enterprise value to EBIT forward. The content appears to be a stub or a section of a larger financial data page, primarily presenting market details and navigation links rather than a d", "url": "https://www.tradingview.com/symbols/GETTEX-Y7G/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T01:10:41", "published_display": "27 Jun 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of BioAge Labs, Inc. \u2013 GETTEX:Y7G", "summary": "This article provides financial information for BioAge Labs, Inc. (GETTEX:Y7G), specifically focusing on its enterprise value to revenue forward. The content is presented as a market data page, offering an overview of the company's financials on TradingView.", "url": "https://www.tradingview.com/symbols/GETTEX-Y7G/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T19:41:41", "published_display": "26 Jun 2026 19:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioAge Labs (BIOA) Tests BGE-102 in Phase 2 Trial, But What Does It Signal Strategically?", "summary": "BioAge Labs has initiated a Phase 2 trial (QUELL-CV) for its drug BGE-102, targeting obesity patients with elevated hsCRP and cardiovascular risk factors. This strategic move aims to validate BGE-102 as a cardiometabolic inflammation therapy, transforming BioAge's investment narr", "url": "https://www.sahmcapital.com/news/content/bioage-labs-bioa-tests-bge-102-in-phase-2-trial-but-what-does-it-signal-strategically-2026-06-25", "source_name": "Sahm", "published_at": "2026-06-26T19:41:41", "published_display": "26 Jun 2026 19:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioAge Labs, Inc. Actuals & Estimates (NASDAQ:BIOA)", "summary": "This article provides an overview of BioAge Labs, Inc. (NASDAQ:BIOA) stock, including its current price, historical performance, analyst forecasts, and financial data. It highlights the company's significant stock price increase over the last year and offers details on its latest", "url": "https://www.tradingview.com/symbols/NASDAQ-BIOA/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T07:10:41", "published_display": "26 Jun 2026 07:10", "sentiment": "positive", "sentiment_pct": 76, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioAge Labs, Inc. Actuals & Estimates (GETTEX:Y7G)", "summary": "This article provides financial actuals and estimates for BioAge Labs, Inc. (GETTEX:Y7G), including its current stock price, historical performance, analyst forecasts, and key financial metrics like revenue, net income, and EBITDA. It also addresses frequently asked questions reg", "url": "https://www.tradingview.com/symbols/GETTEX-Y7G/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T02:09:52", "published_display": "26 Jun 2026 02:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of BioAge Labs, Inc. \u2013 GETTEX:Y7G", "summary": "This article provides financial information for BioAge Labs, Inc. (GETTEX:Y7G), specifically focusing on its enterprise value to EBITDA forward. It indicates a lack of current trading data (\"No trades\") and highlights that the information is made by humans.", "url": "https://www.tradingview.com/symbols/GETTEX-Y7G/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T00:42:06", "published_display": "26 Jun 2026 00:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioAge Labs (BIOA) Is Up 14.2% After Starting Phase 2 Trial Of Oral NLRP3 Inhibitor", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/bioage-labs-bioa-14-2-002250499.html", "source_name": "Simply Wall St.", "published_at": "2026-06-25T00:22:50+00:00", "published_display": "25 Jun 2026 00:22", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioAge Labs: Developing A 'Pipeline In A Pill' (NASDAQ:BIOA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxOaFFqVUZxT3cxT2t2Vl9Na1NyVXdzZWFuNUFnc0N2Tk1LWVRUUGRWZUhRWEF5WTRlcFhXZFdKOExmRm1iVVQxUnJaM1ZyVXF1bXVFbGp2YzZXcUtjX1oyTHdNMWNMd3ZWN0xFQUdMOWNGbU5GdFJDdEFjMWRhNEY3VTZFZWxPLTA?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioAge Labs Doses First Participant in Phase 2 Trial of BGE-102 for Cardiovascular Risk", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/bioage-labs-doses-first-participant-125458711.html", "source_name": "MT Newswires", "published_at": "2026-06-16T12:54:58+00:00", "published_display": "16 Jun 2026 12:54", "sentiment": "negative", "sentiment_pct": 42, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioAge Labs Announces First Participant Dosed in QUELL-CV, a Phase 2 Proof-of-Concept Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Patients at Elevated Cardiovascular Risk", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/bioage-labs-announces-first-participant-120000234.html", "source_name": "GlobeNewswire", "published_at": "2026-06-16T12:00:00+00:00", "published_display": "16 Jun 2026 12:00", "sentiment": "negative", "sentiment_pct": 42, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioAge Labs (BIOA) director receives 22,000 stock options at $15.48 strike", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxNcEtpYzJZQllUb3QyT3cwa3h3UVFFZWxxRmpIM3dsNDRJdG5Db0ZvaFV2OVFhOWpHQ0NOZ2htNXBmYTE5RnJhTVQxTk9BOHl5azIydjYyOEZVRWpoVUlCLUdPLUJyN0RsSF9keXhZZ3FOUERjemJvbnVPZkxKWThhRmxPdFpLS3hMbnJYLThNRHMxdkpGYzJraTBGdU04am1TTndhSHY3SlZ2ZTlZMWZV?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioAge Labs (BIOA) director James Healy receives 22,000 stock options at $15.48", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxOTlBfOE9DZE0yY1VLVkRJbzNUSzVBckJuWHBQa3pyTm5LWU5mUm8xUFZqYWszUFhzWENjSUE2dmE1RE9LS0l4c1JQdncwWlllVWV1LWY4X2txSW1NdEZLRExsSEMxNTNCVl9ZVGk1WTBEcUZmQXZmZzl4cVBwN0QxMnJZOHQyQmtxX3RzOUUtdmVzRXFZZ1V3NmVzVW1hd2lTRE1QVHVrTGVHR0VQTG9J?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioAge Labs Eyes Key BGE-102 Readouts in Heart Risk and Diabetic Eye Disease", "summary": "", "url": "https://finance.yahoo.com/m/c0631655-2fe0-33e4-a591-2d6c30a0823f/bioage-labs-eyes-key-bge-102.html", "source_name": "MarketBeat", "published_at": "2026-06-06T12:04:44+00:00", "published_display": "06 Jun 2026 12:04", "sentiment": "negative", "sentiment_pct": 42, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Roth Capital Partners Initiates BioAge Labs at Buy With $36 Price Target", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/roth-capital-partners-initiates-bioage-104134422.html", "source_name": "MT Newswires", "published_at": "2026-05-27T10:41:34+00:00", "published_display": "27 May 2026 10:41", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioAge Labs to Present at Upcoming Investor Conferences", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/bioage-labs-present-upcoming-investor-130000659.html", "source_name": "GlobeNewswire", "published_at": "2026-05-22T13:00:00+00:00", "published_display": "22 May 2026 13:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is BioAge Labs, Inc. (BIOA) a Top Longevity Biotech Stock to Watch After New Analyst Coverage?", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxOdllBOEZpOXA5bjBhTktjUUVhdlZoWWgzMlRFbmVpelZoSzIwcFJnMjNVVGVVSVFGQU45Ykh3SXdRUEtHeUNuemRMcFJobzFQaWthZ1VVVU9aQV8xZGhKOExIS3F6MFJqck83ZUNLTWlVeGRCQUpjZWgxa0hCQjNIZ1gtaU9sOU9Fa0FyT1pPb1p0dGY3Tkx1bg?oc=5", "source_name": "Market source", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Beat: BioAge Labs, Inc. (NASDAQ:BIOA) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wall Street Analysts Predict an 183.67% Upside in BioAge Labs, Inc. (BIOA): Here's What You Should Know", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPRVhtU2w4Z2s1bHJPcjhxY2dFMW5SRFN0Rlo5dDg3d2h0VldIUVZNTGVUbVdMQXdYcFc3cTVpeUhLNnNmWk1meml3aGlObkYyOGFuWjlub05ITzB5eWZBMGQ3WTRjMEIwQ3VRQWM3VEN4bEhraE5VSDR3ZVZNYzMzSHlnTmVmdi0tcTdMMlV3WlB3aHJONjZIN3UzVG56dw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BGE-102 Data Inspires Confidence for BioAge Labs (BIOA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxPQ3JFNHdsWmt5eUxfY0dvSDdwX0Qyc3RGRTFyRG1ScVZIZ1Z6NzBJMkx2UUt0QnF5VFNDNkh4NEFQU3d3Zk1PZGVkc3dGLUg4QnF1akNlRkxXdEI4RUhEUnFraF9rRGx2VVlWN00wWWdyaG5laVhqM3F4TEtCTzM2Tk5Wa3lGbEVZTFZReVZxYWJEbGJJTzFIaTdyTVRiNFdpUmt3?oc=5", "source_name": "Market source", "published_at": "2026-03-31T07:00:00+00:00", "published_display": "31 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioAge Labs Reports Full Year 2025 Financial Results and Provides Business Updates from the Fourth Quarter of 2025", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAJBVV95cUxNeGVqUllzbmd1U2NlWUVIZ1MwVllPMmpnZXp6WG9HOVZiZGFSUHFtMUlPQzNyRjdoendYcjMyU0NXYmRfRXdzT0J1UHEzby10dWpRb0pjeWgtQzdXVFFfVmpqS3RUT0tWTEdwejZaOGUzZ3R2U1lqOW9zS0xiSHFzOU96eXpYUXVldDM3X1NPai1LYkZQeFhvRF9zQlBBdHM1ZVVCTjZQS3F5NXZQd3NjbVBfNkQ5MmtzNE1ybVBrLTB6Y1ZjV2pVcEl2UkF0aWxOVFNQcTlJUTJPcE9ieFR3NjVmenhKZFBrb1EzWlZnOFU3UVZhQWFvVVg3VkhMamJVQTFJN1BPTlpibUdYa0xoUzJUWks?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-03-24T07:00:00+00:00", "published_display": "24 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioAge says oral drug cut a heart-risk marker 86% in Phase 1", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxPeW9yN0VXRDNtUVNjTEZpZHlQeDlmRXpXS0lWeHZmUld2OTh2cnoyNkN1bUJ1OVZFYVk2aEY5WFdKNWR6YnRPY1Y5MkNPRG5yZnRSWVZ6MURTQnRaczhzd1JpVy1CdDlYYVE5RGQyNEM0SWt3YkpNeUlvSHZxSnRCNnBEcmVqSzRTYmJpWEJJaXk4eXU3Q2k0YUt2WkJWYlVBQmNEYXhGSkkzX2thZGhTcHZJS1dWNko1M2RkRXlR?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-24T07:00:00+00:00", "published_display": "24 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioAge Labs (BIOA) Heavy Quarterly Loss Reinforces Bearish Community Narrative On Profitability", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3gFBVV95cUxQQ2lud0szeFZIbGh5NGVMRldsUnh0ekFvYnhaM08ydmNkSW9qd3JhRVBvRFlZd0ozSnFJaC1DSGtqWHN4VGlIS0ZIWGt0MVlmZkp0MnFnQlZzYWF5bGVtalRxbUdmb2ZkSDdCNkQzZUtXM3FjcEtQQjRYa0dqN3ZTSUlNV3hXSTBQX0dLc3lBWHZhcXV0ZWVpRFdjVkVWSThMMFNIYWxxaWw2alN3NUJaUk1uZk1LYU1jTDQxTDRzVmc5TUUySkdoS1dBV20zQXVnQ3gyUEF2UGRVQVlJS3fSAeMBQVVfeXFMT256YVNPUHh3TjlJS2lEMGFVUFZzZ3NWcHlkZWFrSHlWWjhoZEJuVGJVQlQtaGhkT0tid2dHdFhiNlNGczVDdExKUnlEeXV2MkZaWlZLSWVSd1RyNFE1LVV2b3FVeUlFYnNHYndzVlNLVDJWRmNRN3hldnRMNk5BRHpwX0FkM1hoRS1Bb0E3eEc2SHFRZ2lQRnRpbE1sVWNMUmJFbzBKMXdsVjlmdkRVQ1JMSk9YTFgwOXowVTJUcE9OV3NGZXlRampRcmNnbU11QUp2dG9nU1R1ck1UUWcwVmhOWk0?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-24T07:00:00+00:00", "published_display": "24 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioAge stock falls after announcing $75 million public offering", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxOR2lYTnJiV3RRMS1mOHY3YllqWFREbU9nSGZWNG5mRk9BTmZQUlh0SVJFRy1JMVdLakpSRXJKeDl5NTh1ZThoSENQc2lrcDJrVmRVbEM4SFhxQU9FUmZKWTc3S3JaekFpZF9zZVMtN29RaVBnMW9JTllaSzNaRnU1X19qX1ZuSHM1SU40bUtxRzRNN1oxakswcXlZVDhJWUcyeU5IY25MN2hqYTdsZDRnX3hEVW5ieldyb3UzMEE1T2hwdw?oc=5", "source_name": "Investing.com", "published_at": "2026-01-20T08:00:00+00:00", "published_display": "20 Jan 2026 08:00", "sentiment": "negative", "sentiment_pct": 22, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "2 Reasons I Wouldn't Touch BioAge Labs Stock With a 10-Foot Pole", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPNDB5M2lVX0d1T0RDN3ZBRUM1T0dQSS1Bb3kxeTJ4bzk3N3g1dlRiTFlKOFpIT2tDRGRveVZTMUdvZXJuRzdfc3FqenZjclBuS1FYZXd3YzZkVDA3RlhTY0kyTWN5c2RPcVQxU3hHVEUtc05yQTFTWEo3ODhHcl9hOThVcWVfNVI2VjVERnd3Sk9iRlM1X3Jkbw?oc=5", "source_name": "The Motley Fool", "published_at": "2025-12-13T08:00:00+00:00", "published_display": "13 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BIOA Stock Price and Chart \u2014 NASDAQ:BIOA", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE9Zb19pcHlTZzJLeEFxZktvYUhCZUg2MTRWZ3lzTVM4SXNBNHlQNnZ4YU5XV05wYXdCeVhfUFlFTmlVcFUtZG16cDYyVnVTbUpWemVaQ01VZTRWYUNT?oc=5", "source_name": "TradingView", "published_at": "2024-12-03T08:00:00+00:00", "published_display": "03 Dec 2024 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioAge Labs (BIOA) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTFBYYVl3VXZjYzRrbURBYnNsa2V5N1VpR3dUbUNnSFJOb0xPMHZ0TkttUTJwWUpNMmxxUDJGbFJQUTBNR3lEc3JYelhZeDQ5aTdvX3F2eVZTT3FyQQ?oc=5", "source_name": "MarketBeat", "published_at": "2015-07-01T15:32:19+00:00", "published_display": "01 Jul 2015 15:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "HitGen Partner BioAge Labs Doses First Participant In Phase 2 Trial Of BGE-102", "summary": "HitGen's partner, BioAge Labs, has dosed the first participant in its Phase 2 trial of BGE-102. This marks a significant step forward in the development of the therapeutic candidate.", "url": "https://www.tradingview.com/news/reuters.com,2026:newsml_TUA88ZXV4:0-hitgen-partner-bioage-labs-doses-first-participant-in-phase-2-trial-of-bge-102/", "source_name": "TradingView", "published_at": "2026-07-14T15:13:40", "published_display": "14 Jul 2026 15:13", "sentiment": "positive", "sentiment_pct": 69, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "HitGen partner BioAge begins phase 2 trial of BGE-102", "summary": "HitGen Inc. announced that its partner BioAge Labs has started a Phase 2 clinical trial for BGE-102, an oral small molecule NLRP3 inhibitor aimed at reducing cardiovascular risk. The trial, named QUELL-CV, will evaluate optimal dosing for future Phase 3 development and is expecte", "url": "https://www.investing.com/news/company-news/hitgen-partner-bioage-begins-phase-2-trial-of-bge102-93CH-4791083", "source_name": "Investing.com", "published_at": "2026-07-14T13:46:15", "published_display": "14 Jul 2026 13:46", "sentiment": "positive", "sentiment_pct": 91, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "HitGen Partner BioAge Labs Doses First Participant in Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor for Cardiovascular Risk Reduction", "summary": "HitGen's partner, BioAge Labs, has dosed the first participant in its Phase 2 QUELL-CV trial for BGE-102, a novel oral NLRP3 inhibitor developed using HitGen's DNA-Encoded Library (DEL) technology. This trial aims to determine optimal dosing for cardiovascular risk reduction, wit", "url": "https://www.prnewswire.com/news-releases/hitgen-partner-bioage-labs-doses-first-participant-in-phase-2-trial-of-bge-102-a-novel-oral-nlrp3-inhibitor-for-cardiovascular-risk-reduction-302824829.html", "source_name": "PR Newswire", "published_at": "2026-07-14T13:30:15", "published_display": "14 Jul 2026 13:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Broad Russell Growth Index Inclusion Could Shape BioAge Labs (BIOA) Investor Exposure", "summary": "BioAge Labs (BIOA) was recently added to several Russell Growth Benchmark Indexes, increasing its visibility among institutional investors but not fundamentally changing its core investment risks or near-term catalysts. The investment case hinges on the success of its lead asset ", "url": "https://www.sahmcapital.com/news/content/how-broad-russell-growth-index-inclusion-could-shape-bioage-labs-bioa-investor-exposure-2026-07-10", "source_name": "Sahm", "published_at": "2026-07-11T01:09:23", "published_display": "11 Jul 2026 01:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioAge advances inflammaging drug into Phase 2", "summary": "BioAge has initiated its Phase 2 QUELL-CV trial to evaluate its NLRP3 inflammasome inhibitor, BGE-102, for cardiovascular inflammatory burden. This drug was discovered through human longevity datasets, aiming to address chronic inflammation (inflammaging) which is a key hallmark ", "url": "https://longevity.technology/news/bioage-advances-inflammaging-drug-into-phase-2/", "source_name": "Longevity.Technology", "published_at": "2026-07-07T16:12:12", "published_display": "07 Jul 2026 16:12", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of BioAge Labs, Inc. \u2013 NASDAQ:BIOA", "summary": "This article provides the \"Price to sales forward\" metric for BioAge Labs, Inc. (NASDAQ:BIOA). The data is presented within the context of TradingView's financial overview for the company, accessible through its platform.", "url": "https://www.tradingview.com/symbols/NASDAQ-BIOA/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-07T03:41:07", "published_display": "07 Jul 2026 03:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of BioAge Labs, Inc. \u2013 DUS:Y7G", "summary": "This article displays information regarding the \"Price to earnings forward\" metric for BioAge Labs, Inc. (DUS:Y7G) on the Dusseldorf Stock Exchange. It indicates that no specific value, change, or percentage change for this financial metric was available at the time of publicatio", "url": "https://www.tradingview.com/symbols/DUS-Y7G/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-07T00:39:19", "published_display": "07 Jul 2026 00:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of BioAge Labs, Inc. \u2013 DUS:Y7G", "summary": "This page from TradingView provides financial information for BioAge Labs, Inc. (DUS:Y7G), specifically focusing on its Enterprise Value to EBITDA forward. The content indicates that market data is provided by ICE Data Services and FactSet, highlighting key financial metrics for ", "url": "https://www.tradingview.com/symbols/DUS-Y7G/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-06T21:40:01", "published_display": "06 Jul 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bioage Labs stock hits 52-week high at 25.8 USD", "summary": "Bioage Labs (BIOA) stock recently hit a 52-week high of $25.8, currently trading at $25.53 with a market capitalization of $1.12 billion, reflecting a 486% increase over the past year. This surge is supported by positive developments, including the dosing of the first participant", "url": "https://www.investing.com/news/company-news/bioage-labs-stock-hits-52week-high-at-258-usd-93CH-4776825", "source_name": "Investing.com", "published_at": "2026-07-06T14:41:07", "published_display": "06 Jul 2026 14:41", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why BioAge Labs (BIOA) Is Up 6.3% After Starting QUELL-CV Phase 2 Trial For BGE-102", "summary": "BioAge Labs (BIOA) has started its QUELL-CV Phase 2 trial for BGE-102, an oral NLRP3 inhibitor targeting cardiovascular risk reduction, leading to a 6.3% increase in its stock price. This move advances the company's pipeline and focuses investor attention on its inflammation-targ", "url": "https://www.sahmcapital.com/news/content/why-bioage-labs-bioa-is-up-63-after-starting-quell-cv-phase-2-trial-for-bge-102-2026-07-02", "source_name": "Sahm", "published_at": "2026-07-03T23:40:02", "published_display": "03 Jul 2026 23:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bioage Labs Insider Sold Shares Worth $1,576,752, According to a Recent SEC Filing", "summary": "An insider at Bioage Labs recently sold shares totaling $1,576,752, as detailed in a recent SEC filing. This transaction provides insights into insider activities at the company, which can often be a point of interest for investors.", "url": "https://www.moomoo.com/news/post/72352036/bioage-labs-insider-sold-shares-worth-1576752-according-to-a", "source_name": "Moomoo", "published_at": "2026-07-01T21:40:38", "published_display": "01 Jul 2026 21:40", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] BioAge Labs, Inc. Insider Trading Activity", "summary": "BioAge Labs, Inc.'s Principal Accounting Officer, Shane Barton, engaged in insider trading activity by exercising stock options and selling common stock shares in late June. These transactions, totaling 62,566 shares sold for approximately $1.58 million, were executed under a pre", "url": "https://www.stocktitan.net/sec-filings/BIOA/form-4-bio-age-labs-inc-insider-trading-activity-aab271d3fad7.html", "source_name": "Stock Titan", "published_at": "2026-07-01T20:53:58", "published_display": "01 Jul 2026 20:53", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioAge Labs principal accounting officer sells $1.57m in stock", "summary": "Shane Barton, Principal Accounting Officer at BioAge Labs, Inc. (NASDAQ:BIOA), sold 62,566 shares of the company's common stock for approximately $1.57 million between June 29 and June 30, 2026. These sales occurred after Barton acquired 59,934 shares through stock options and we", "url": "https://www.investing.com/news/insider-trading-news/bioage-labs-principal-accounting-officer-sells-157m-in-stock-93CH-4771539", "source_name": "Investing.com", "published_at": "2026-07-01T20:40:38", "published_display": "01 Jul 2026 20:40", "sentiment": "negative", "sentiment_pct": 35, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioAge Labs principal accounting officer sells $1.57m in stock By Investing.com", "summary": "BioAge Labs' principal accounting officer, Shane Barton, sold 62,566 shares of BioAge Labs (NASDAQ: BIOA) common stock for approximately $1.57 million across two trading days. These sales occurred after Barton exercised stock options to acquire 59,934 shares and were executed und", "url": "https://ca.investing.com/news/stock-market-news/bioage-labs-principal-accounting-officer-sells-157m-in-stock-93CH-4717028", "source_name": "Investing.com Canada", "published_at": "2026-07-01T20:39:59", "published_display": "01 Jul 2026 20:39", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Bioage Labs Inc For: 1 July By Investing.com", "summary": "This article reports on a Form 4 filing by Bioage Labs Inc. for July 1st, published by Investing.com. It also includes a stock market overview with various indices, commodity prices, and individual stock performances, alongside popular news headlines.", "url": "https://ca.investing.com/news/stock-market-news/form-4-bioage-labs-inc-for-1-july-93CH-4717041", "source_name": "Investing.com Canada", "published_at": "2026-07-01T20:39:58", "published_display": "01 Jul 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BIOA (NASDAQ: BIOA) Form 144 filed for 42,350-share proposed sale", "summary": "BioAge Labs, Inc. (NASDAQ: BIOA) has filed a Form 144 indicating a proposed sale of 42,350 shares tied to a stock option exercise, with a planned sale date of June 30, 2026. The filing also reports a recent sale of 42,350 shares on June 29, 2026, generating $1,067,577.87, with Fi", "url": "https://www.stocktitan.net/sec-filings/BIOA/144-bio-age-labs-inc-sec-filing-06639cfc10ad.html", "source_name": "Stock Titan", "published_at": "2026-06-30T20:22:32", "published_display": "30 Jun 2026 20:22", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is BioAge Labs, Inc. (BIOA) Stock Positioned for Growth With New Phase 2 Cardiovascular Study Initiation?", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxNbnE4RUI3YzhkV1RkSkprZ2hoR2lYWE9fUkhIQkxSNEk0b0FucjZ4bUtlSVJqOW0wT0ZBZmFHZDZQbUlGNjY0LW4xXzZJdGFXNDBManMyWjlTTUU4WTJNU0xGNEppa0pTWVpzd2pYY18yX1ZFQUVfSmlMY3YwVU1tMHY0SUl3RlZtUkZBNUZGVWc?oc=5", "source_name": "Market source", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 BioAge Labs For: 29 June By Investing.com", "summary": "This article from Investing.com announces the filing of Form 144 for BioAge Labs on June 29. It briefly mentions the stock symbol BIOA, which saw a 5.01% increase, and is published by \u00a9 Reuters. The content mainly consists of market data and unrelated trending news and stock perf", "url": "https://ca.investing.com/news/stock-market-news/form-144-bioage-labs-for-29-june-93CH-4712570", "source_name": "Investing.com Canada", "published_at": "2026-06-29T21:09:16", "published_display": "29 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BIOA (BIOA) Form 144 lists proposed sales of 2,632 and 39,718 shares", "summary": "BioAge Labs, Inc. (BIOA) has filed a Form 144 notice with the SEC, indicating proposed sales of Common stock. The filing details two transactions: 2,632 \"IPO Shares\" dated September 26, 2024, and 39,718 shares from a \"Stock Option Exercise\" dated June 29, 2026. Fidelity Brokerage", "url": "https://www.stocktitan.net/sec-filings/BIOA/144-bio-age-labs-inc-sec-filing-ae490a06ed9a.html", "source_name": "Stock Titan", "published_at": "2026-06-29T20:09:16", "published_display": "29 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioAge Labs, Inc.(NasdaqGS: BIOA) added to Russell Microcap Growth Benchmark Index", "summary": "BioAge Labs, Inc. (NasdaqGS: BIOA) has been added to multiple Russell benchmark indices, including the Russell Microcap Growth, Russell 2000 Growth, Russell 3000E Growth, and Russell Small Cap Comp Growth. This inclusion is a significant milestone for the clinical-stage biopharma", "url": "https://www.marketscreener.com/news/bioage-labs-inc-nasdaqgs-bioa-added-to-russell-microcap-growth-benchmark-index-ce7f5fded08df123", "source_name": "marketscreener.com", "published_at": "2026-06-29T13:09:16", "published_display": "29 Jun 2026 13:09", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioAge Labs, Inc.(NasdaqGS: BIOA) added to Russell 2000 Growth Benchmark", "summary": "BioAge Labs, Inc. (NasdaqGS:BIOA) has been added to the Russell 2000 Growth Benchmark, a significant development for the clinical-stage biopharmaceutical company. The company focuses on developing therapeutic product candidates for metabolic diseases, such as obesity, by targetin", "url": "https://www.marketscreener.com/news/bioage-labs-inc-nasdaqgs-bioa-added-to-russell-2000-growth-benchmark-ce7f5fded18df026", "source_name": "marketscreener.com", "published_at": "2026-06-29T11:41:03", "published_display": "29 Jun 2026 11:41", "sentiment": "positive", "sentiment_pct": 86, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioAge Labs (BIOA) Following QUELL CV Trial Start Is The Stock A Bargain", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of BioAge Labs, Inc. \u2013 NASDAQ:BIOA", "summary": "This article provides a financial metric\u2014enterprise value to EBIT forward\u2014for BioAge Labs, Inc. (NASDAQ: BIOA). It serves as a financial data point without further analysis or contextual information. The content primarily focuses on the stock's listing and basic financial overvie", "url": "https://www.tradingview.com/symbols/NASDAQ-BIOA/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T14:41:41", "published_display": "27 Jun 2026 14:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of BioAge Labs, Inc. \u2013 GETTEX:Y7G", "summary": "This article provides financial information for BioAge Labs, Inc. (GETTEX:Y7G) focusing on its enterprise value to EBIT forward. The content appears to be a stub or a section of a larger financial data page, primarily presenting market details and navigation links rather than a d", "url": "https://www.tradingview.com/symbols/GETTEX-Y7G/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T01:10:41", "published_display": "27 Jun 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of BioAge Labs, Inc. \u2013 GETTEX:Y7G", "summary": "This article provides financial information for BioAge Labs, Inc. (GETTEX:Y7G), specifically focusing on its enterprise value to revenue forward. The content is presented as a market data page, offering an overview of the company's financials on TradingView.", "url": "https://www.tradingview.com/symbols/GETTEX-Y7G/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T19:41:41", "published_display": "26 Jun 2026 19:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioAge Labs (BIOA) Tests BGE-102 in Phase 2 Trial, But What Does It Signal Strategically?", "summary": "BioAge Labs has initiated a Phase 2 trial (QUELL-CV) for its drug BGE-102, targeting obesity patients with elevated hsCRP and cardiovascular risk factors. This strategic move aims to validate BGE-102 as a cardiometabolic inflammation therapy, transforming BioAge's investment narr", "url": "https://www.sahmcapital.com/news/content/bioage-labs-bioa-tests-bge-102-in-phase-2-trial-but-what-does-it-signal-strategically-2026-06-25", "source_name": "Sahm", "published_at": "2026-06-26T19:41:41", "published_display": "26 Jun 2026 19:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioAge Labs, Inc. Actuals & Estimates (NASDAQ:BIOA)", "summary": "This article provides an overview of BioAge Labs, Inc. (NASDAQ:BIOA) stock, including its current price, historical performance, analyst forecasts, and financial data. It highlights the company's significant stock price increase over the last year and offers details on its latest", "url": "https://www.tradingview.com/symbols/NASDAQ-BIOA/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T07:10:41", "published_display": "26 Jun 2026 07:10", "sentiment": "positive", "sentiment_pct": 76, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioAge Labs, Inc. Actuals & Estimates (GETTEX:Y7G)", "summary": "This article provides financial actuals and estimates for BioAge Labs, Inc. (GETTEX:Y7G), including its current stock price, historical performance, analyst forecasts, and key financial metrics like revenue, net income, and EBITDA. It also addresses frequently asked questions reg", "url": "https://www.tradingview.com/symbols/GETTEX-Y7G/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T02:09:52", "published_display": "26 Jun 2026 02:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of BioAge Labs, Inc. \u2013 GETTEX:Y7G", "summary": "This article provides financial information for BioAge Labs, Inc. (GETTEX:Y7G), specifically focusing on its enterprise value to EBITDA forward. It indicates a lack of current trading data (\"No trades\") and highlights that the information is made by humans.", "url": "https://www.tradingview.com/symbols/GETTEX-Y7G/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T00:42:06", "published_display": "26 Jun 2026 00:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioAge Labs (BIOA) Is Up 14.2% After Starting Phase 2 Trial Of Oral NLRP3 Inhibitor", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/bioage-labs-bioa-14-2-002250499.html", "source_name": "Simply Wall St.", "published_at": "2026-06-25T00:22:50+00:00", "published_display": "25 Jun 2026 00:22", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioAge Labs: Developing A 'Pipeline In A Pill' (NASDAQ:BIOA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxOaFFqVUZxT3cxT2t2Vl9Na1NyVXdzZWFuNUFnc0N2Tk1LWVRUUGRWZUhRWEF5WTRlcFhXZFdKOExmRm1iVVQxUnJaM1ZyVXF1bXVFbGp2YzZXcUtjX1oyTHdNMWNMd3ZWN0xFQUdMOWNGbU5GdFJDdEFjMWRhNEY3VTZFZWxPLTA?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioAge Labs Doses First Participant in Phase 2 Trial of BGE-102 for Cardiovascular Risk", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/bioage-labs-doses-first-participant-125458711.html", "source_name": "MT Newswires", "published_at": "2026-06-16T12:54:58+00:00", "published_display": "16 Jun 2026 12:54", "sentiment": "negative", "sentiment_pct": 42, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioAge Labs Announces First Participant Dosed in QUELL-CV, a Phase 2 Proof-of-Concept Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Patients at Elevated Cardiovascular Risk", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/bioage-labs-announces-first-participant-120000234.html", "source_name": "GlobeNewswire", "published_at": "2026-06-16T12:00:00+00:00", "published_display": "16 Jun 2026 12:00", "sentiment": "negative", "sentiment_pct": 42, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioAge Labs (BIOA) director receives 22,000 stock options at $15.48 strike", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxNcEtpYzJZQllUb3QyT3cwa3h3UVFFZWxxRmpIM3dsNDRJdG5Db0ZvaFV2OVFhOWpHQ0NOZ2htNXBmYTE5RnJhTVQxTk9BOHl5azIydjYyOEZVRWpoVUlCLUdPLUJyN0RsSF9keXhZZ3FOUERjemJvbnVPZkxKWThhRmxPdFpLS3hMbnJYLThNRHMxdkpGYzJraTBGdU04am1TTndhSHY3SlZ2ZTlZMWZV?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioAge Labs (BIOA) director James Healy receives 22,000 stock options at $15.48", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxOTlBfOE9DZE0yY1VLVkRJbzNUSzVBckJuWHBQa3pyTm5LWU5mUm8xUFZqYWszUFhzWENjSUE2dmE1RE9LS0l4c1JQdncwWlllVWV1LWY4X2txSW1NdEZLRExsSEMxNTNCVl9ZVGk1WTBEcUZmQXZmZzl4cVBwN0QxMnJZOHQyQmtxX3RzOUUtdmVzRXFZZ1V3NmVzVW1hd2lTRE1QVHVrTGVHR0VQTG9J?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioAge Labs Eyes Key BGE-102 Readouts in Heart Risk and Diabetic Eye Disease", "summary": "", "url": "https://finance.yahoo.com/m/c0631655-2fe0-33e4-a591-2d6c30a0823f/bioage-labs-eyes-key-bge-102.html", "source_name": "MarketBeat", "published_at": "2026-06-06T12:04:44+00:00", "published_display": "06 Jun 2026 12:04", "sentiment": "negative", "sentiment_pct": 42, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Roth Capital Partners Initiates BioAge Labs at Buy With $36 Price Target", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/roth-capital-partners-initiates-bioage-104134422.html", "source_name": "MT Newswires", "published_at": "2026-05-27T10:41:34+00:00", "published_display": "27 May 2026 10:41", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioAge Labs to Present at Upcoming Investor Conferences", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/bioage-labs-present-upcoming-investor-130000659.html", "source_name": "GlobeNewswire", "published_at": "2026-05-22T13:00:00+00:00", "published_display": "22 May 2026 13:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is BioAge Labs, Inc. (BIOA) a Top Longevity Biotech Stock to Watch After New Analyst Coverage?", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxOdllBOEZpOXA5bjBhTktjUUVhdlZoWWgzMlRFbmVpelZoSzIwcFJnMjNVVGVVSVFGQU45Ykh3SXdRUEtHeUNuemRMcFJobzFQaWthZ1VVVU9aQV8xZGhKOExIS3F6MFJqck83ZUNLTWlVeGRCQUpjZWgxa0hCQjNIZ1gtaU9sOU9Fa0FyT1pPb1p0dGY3Tkx1bg?oc=5", "source_name": "Market source", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Beat: BioAge Labs, Inc. (NASDAQ:BIOA) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wall Street Analysts Predict an 183.67% Upside in BioAge Labs, Inc. (BIOA): Here's What You Should Know", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPRVhtU2w4Z2s1bHJPcjhxY2dFMW5SRFN0Rlo5dDg3d2h0VldIUVZNTGVUbVdMQXdYcFc3cTVpeUhLNnNmWk1meml3aGlObkYyOGFuWjlub05ITzB5eWZBMGQ3WTRjMEIwQ3VRQWM3VEN4bEhraE5VSDR3ZVZNYzMzSHlnTmVmdi0tcTdMMlV3WlB3aHJONjZIN3UzVG56dw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BGE-102 Data Inspires Confidence for BioAge Labs (BIOA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxPQ3JFNHdsWmt5eUxfY0dvSDdwX0Qyc3RGRTFyRG1ScVZIZ1Z6NzBJMkx2UUt0QnF5VFNDNkh4NEFQU3d3Zk1PZGVkc3dGLUg4QnF1akNlRkxXdEI4RUhEUnFraF9rRGx2VVlWN00wWWdyaG5laVhqM3F4TEtCTzM2Tk5Wa3lGbEVZTFZReVZxYWJEbGJJTzFIaTdyTVRiNFdpUmt3?oc=5", "source_name": "Market source", "published_at": "2026-03-31T07:00:00+00:00", "published_display": "31 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioAge Labs Reports Full Year 2025 Financial Results and Provides Business Updates from the Fourth Quarter of 2025", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAJBVV95cUxNeGVqUllzbmd1U2NlWUVIZ1MwVllPMmpnZXp6WG9HOVZiZGFSUHFtMUlPQzNyRjdoendYcjMyU0NXYmRfRXdzT0J1UHEzby10dWpRb0pjeWgtQzdXVFFfVmpqS3RUT0tWTEdwejZaOGUzZ3R2U1lqOW9zS0xiSHFzOU96eXpYUXVldDM3X1NPai1LYkZQeFhvRF9zQlBBdHM1ZVVCTjZQS3F5NXZQd3NjbVBfNkQ5MmtzNE1ybVBrLTB6Y1ZjV2pVcEl2UkF0aWxOVFNQcTlJUTJPcE9ieFR3NjVmenhKZFBrb1EzWlZnOFU3UVZhQWFvVVg3VkhMamJVQTFJN1BPTlpibUdYa0xoUzJUWks?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-03-24T07:00:00+00:00", "published_display": "24 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioAge says oral drug cut a heart-risk marker 86% in Phase 1", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxPeW9yN0VXRDNtUVNjTEZpZHlQeDlmRXpXS0lWeHZmUld2OTh2cnoyNkN1bUJ1OVZFYVk2aEY5WFdKNWR6YnRPY1Y5MkNPRG5yZnRSWVZ6MURTQnRaczhzd1JpVy1CdDlYYVE5RGQyNEM0SWt3YkpNeUlvSHZxSnRCNnBEcmVqSzRTYmJpWEJJaXk4eXU3Q2k0YUt2WkJWYlVBQmNEYXhGSkkzX2thZGhTcHZJS1dWNko1M2RkRXlR?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-24T07:00:00+00:00", "published_display": "24 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioAge Labs (BIOA) Heavy Quarterly Loss Reinforces Bearish Community Narrative On Profitability", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-24T07:00:00+00:00", "published_display": "24 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioAge stock falls after announcing $75 million public offering", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxOR2lYTnJiV3RRMS1mOHY3YllqWFREbU9nSGZWNG5mRk9BTmZQUlh0SVJFRy1JMVdLakpSRXJKeDl5NTh1ZThoSENQc2lrcDJrVmRVbEM4SFhxQU9FUmZKWTc3S3JaekFpZF9zZVMtN29RaVBnMW9JTllaSzNaRnU1X19qX1ZuSHM1SU40bUtxRzRNN1oxakswcXlZVDhJWUcyeU5IY25MN2hqYTdsZDRnX3hEVW5ieldyb3UzMEE1T2hwdw?oc=5", "source_name": "Investing.com", "published_at": "2026-01-20T08:00:00+00:00", "published_display": "20 Jan 2026 08:00", "sentiment": "negative", "sentiment_pct": 22, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "2 Reasons I Wouldn't Touch BioAge Labs Stock With a 10-Foot Pole", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPNDB5M2lVX0d1T0RDN3ZBRUM1T0dQSS1Bb3kxeTJ4bzk3N3g1dlRiTFlKOFpIT2tDRGRveVZTMUdvZXJuRzdfc3FqenZjclBuS1FYZXd3YzZkVDA3RlhTY0kyTWN5c2RPcVQxU3hHVEUtc05yQTFTWEo3ODhHcl9hOThVcWVfNVI2VjVERnd3Sk9iRlM1X3Jkbw?oc=5", "source_name": "The Motley Fool", "published_at": "2025-12-13T08:00:00+00:00", "published_display": "13 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BIOA Stock Price and Chart \u2014 NASDAQ:BIOA", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE9Zb19pcHlTZzJLeEFxZktvYUhCZUg2MTRWZ3lzTVM4SXNBNHlQNnZ4YU5XV05wYXdCeVhfUFlFTmlVcFUtZG16cDYyVnVTbUpWemVaQ01VZTRWYUNT?oc=5", "source_name": "TradingView", "published_at": "2024-12-03T08:00:00+00:00", "published_display": "03 Dec 2024 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioAge Labs (BIOA) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTFBYYVl3VXZjYzRrbURBYnNsa2V5N1VpR3dUbUNnSFJOb0xPMHZ0TkttUTJwWUpNMmxxUDJGbFJQUTBNR3lEc3JYelhZeDQ5aTdvX3F2eVZTT3FyQQ?oc=5", "source_name": "MarketBeat", "published_at": "2015-07-01T15:32:19+00:00", "published_display": "01 Jul 2015 15:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 79, "total_relevant": 49, "sentiment_summary": {"positive": 12, "negative": 10, "neutral": 27, "score": 53, "total": 49, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 89, "events": [{"event": "general", "label": "Market update", "weight": 22.35, "count": 40}, {"event": "earnings", "label": "Earnings", "weight": 2.75, "count": 5}, {"event": "analyst", "label": "Analyst action", "weight": 1.65, "count": 3}, {"event": "macro", "label": "Macro sensitivity", "weight": 0.55, "count": 1}], "positive_events": 12, "negative_events": 10}, "market_context": {"has_market_context": true, "latest_close": 24.34, "latest_week": "2026-07-10", "one_week_move": -3.0, "four_week_move": 34.9, "twelve_week_move": 31.6, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 0.941563, "market_dynamics_buy_signal": false, "relative_strength": 59.864322, "fair_value_gap": 114.7, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "positive", "expectation_probability": 62.5567, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-3.0% over one week, +34.9% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 65, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "TradingView", "count": 11}, {"label": "Stock Titan", "count": 6}, {"label": "Investing.com", "count": 4}, {"label": "Market source", "count": 4}, {"label": "Sahm", "count": 3}, {"label": "Investing.com Canada", "count": 3}, {"label": "simplywall.st", "count": 3}, {"label": "GlobeNewswire", "count": 3}], "tiers": [{"label": "Direct company coverage", "count": 49}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 40}, {"label": "Earnings", "count": 5}, {"label": "Analyst action", "count": 3}, {"label": "Macro sensitivity", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "53/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "89/100 classification confidence."}, {"label": "Company focus", "value": "49", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-3.0% over one week, +34.9% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "HitGen Partner BioAge Labs Doses First Participant In Phase 2 Trial Of BGE-102"}], "updated_at": "2026-07-16T11:43:13.253384+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}